Mustang Bio, Inc. (MBIO): Price and Financial Metrics
MBIO Price/Volume Stats
| Current price | $1.43 | 52-week high | $67.00 |
| Prev. close | $1.43 | 52-week low | $1.35 |
| Day low | $1.37 | Volume | 39,851 |
| Day high | $1.46 | Avg. volume | 387,629 |
| 50-day MA | $3.92 | Dividend yield | N/A |
| 200-day MA | $11.64 | Market Cap | 1.37M |
MBIO Stock Price Chart Interactive Chart >
Mustang Bio, Inc. (MBIO) Company Bio
Mustang Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was founded in 2015 and is based in New York, New York. Mustang Bio Inc. is a subsidiary of Fortress Biotech, Inc.
MBIO Price Returns
| 1-mo | N/A |
| 3-mo | -82.68% |
| 6-mo | -87.12% |
| 1-year | -97.26% |
| 3-year | -99.79% |
| 5-year | -99.92% |
| YTD | -83.84% |
| 2024 | -86.89% |
| 2023 | -77.21% |
| 2022 | -76.21% |
| 2021 | -56.14% |
| 2020 | -7.23% |
Continue Researching MBIO
Want to see what other sources are saying about Mustang Bio Inc's financials and stock price? Try the links below:Mustang Bio Inc (MBIO) Stock Price | Nasdaq
Mustang Bio Inc (MBIO) Stock Quote, History and News - Yahoo Finance
Mustang Bio Inc (MBIO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...